Foundation News

2005 Gold Ribbon Gala a Great Success

On Monday, November 21 we hosted our Second Annual Gold Ribbon Gala at the Westin Harbour Castle Hotel in Toronto . It was a night of successful fundraising and friendship building. We also premiered our new Foundation video which you can preview now at http://www.fulfordbrown.com/clients/CCF
Then login with: CCF (case sensitive) and use the password wewillwin (case sensitive)

We are so grateful to all the children and families who allowed us to use their voices and faces in our video. It really has touched many people already. We hope you enjoy watching it too.

Holiday Cards Support our Foundation

A great big THANK YOU to The Printing House (TPH) who has designated our Foundation as one of 2 charities to receive the proceeds from their national Holiday Card Program. Please order your cards today through The Printing House. Please do what you can to sell these cards…share the order form with friends, family and colleagues. The more cards sold, the more money flows into the fight against childhood cancer.

We Will Win Wristbands a Hit in Schools and Communities

Buy a green Childhood Cancer Foundation “We Will Win” wristband – buy some for your friends. Get your workplace to sell them. Wear them. Help find a cure for 10,000 children with cancer across Canada . Show them you care. Only $2.50 each (includes shipping and handling). Call Rachna at 1-800-363-1062 to place your order.
View wristband here!

Upcoming Events

February 15 is International Childhood Cancer Awareness Day

This is a day to focus your fundraising efforts and information sharing on children with cancer and the Childhood Cancer Foundation. Contact us for We Will Win Wristbands and Foundation brochures to help you create a fundraiser or information sharing to help support 10,000 children in Canada who are in treatment for cancer.

Fundraising Success

New Corporate Sponsors on Board

We welcome new corporate sponsors: ING Foundation, Ronald McDonald House Foundation and Hoffmann La Roche and thank them for their generous support of the Childhood Cancer Foundation and our programs to support children and families through their cancer journey.

In the news

Cancer Survivors Often Become 'Lost in Transition'
By Liz Szabo
A report released Monday says the nation's more than 10 million cancer survivors often find themselves "lost in transition," without adequate help dealing with the medical, social and psychological problems that can follow survivors for decades after their illness. People who survive cancer face a number of serious health risks - such as a relapse or second cancer, heart disease, infertility and depression - and frequently grapple with severe debt or job loss, according to the report. It was written by the Institute of Medicine and the National Research Council of the National Academies, private, non-profit groups of experts chartered by Congress to provide science and health policy advice. The study calls for doctors, insurance companies and policymakers to recognize cancer survivorship not as the end of the road but as a distinct and vital phase of continuing care. Traditionally, doctors say, they devoted most of their efforts simply to keeping patients alive. Today, with 64% of adults and 80% of children surviving at least five years with the disease, Stovall says, researchers also are trying to improve patients' quality of life. Today, the report finds, many survivors lack critical information:

* Up to 40% of female Hodgkin's disease survivors aren't aware they are at high risk for breast cancer.
* Only 22% of colorectal cancer survivors know how to tell whether their disease has returned.
* Only half of cancer patients of childbearing age receive information about preserving their fertility.

Cancer Boom in Cancer Drugs
By Aaron Smith
FDA advisors are scrutinizing a raft of cancer drug data this week, including Pfizer's Celebrex, in the latest indication that the drug market is baby-booming for America 's second-biggest killer, cancer. Cancer drug sales are projected to reach $55 billion in 2009, more than double the 2004 tally of $24 billion, according to British research firm IMS Health. The ramp-up, driven by aging baby boomers, is keeping the Food and Drug Administration busy as drugs move through its "fast track" approval process reserved for treatments of cancer and other life-threatening diseases. "[Cancer] is definitely one of the biggest areas of research right now for health care," said Andrew McDonald, analyst for ThinkEquity Partners, who described oncology as a "hot place" for drug makers. "There's a huge unmet need. Cancer is not being cured." The FDA's cancer drug advisory committee on Tuesday will discuss data for half a dozen drugs. Drug makers find that cancer drugs are easier to get approved, said McDonald, because many cancer patients are terminally ill so the FDA allows more side effects. Here are some of the other fast-track drugs the FDA cancer committee is considering:

• Ontak, from Seragen Incorp., for the treatment of cutaneous T-cell lymphoma , which causes the growth of cancerous tumors.
• Depocyt, from SkyePharma, for the treatment of meningitis related to lymphoma .
• Mylotarg, from Wyeth Pharmaceuticals, for the treatment of a specific type of relapsed leukemia in patients 60 or older who are not considered candidates for chemotherapy.
• Campath, from Genzyme-owned Ilex Oncology, for the treatment of a specific type of leukemia related to lymphoma .

AnorMED (AOM.TO) Reports Fiscal 2006 Second Quarter Results, And Progress On Phase III Trials For MOZOBIL(TM) VANCOUVER
In September, Phase II results, from a study involving 25 cancer patients undergoing a stem cell transplant , were published in the medical Journal Blood. These results show that MOZOBIL in combination with G-CSF is a superior stem cell mobilization regimen compared to G-CSF alone, based on the yield of stem cells collected per day, the reduction in stem cell collection time and successful mobilization of patients who failed in the G-CSF alone arm. In fact, 60% of patients in the MOZOBIL + G-CSF arm collected the ideal amount of stem cells in two days, compared to 16% in the G-CSF alone arm. Recruitment into the Phase III trials for MOZOBIL continues to make steady progress.
To date, 98 non-Hodgkin's lymphoma (NHL) patients and 100 multiple myeloma (MM) patients have entered into the Phase III trials. Currently, 33 sites are recruiting NHL patients and 33 sites are recruiting MM patients. We are maintaining our goal to complete Phase III enrollment and three month follow up by the end of calendar year 2006. We also continue to develop our Phase II program for MOZOBIL, to address different segments of the transplant market. Currently we are recruiting patients for five Phase II trials, including a newly initiated trial in poor mobilizers.
We plan to continue expanding our Phase II program, in order to evaluate the potential of MOZOBIL in combination with different therapies and patient populations, such as with Rituxan and in pediatric patients. In addition, investigator sponsored studies are ongoing to evaluate MOZOBIL as a single agent in allogeneic transplantation. Data from some of these studies will be presented at the American Society of Hematology (ASH) meeting in Atlanta , Georgia , December 10th-13th 2005 .

What are you hoping for? 

Please e-mail your thoughts, needs and expectations of this service to Mary Lye at [email protected]. We want this service to be useful to you.

The information in this e-mail message including any attachments is intended only for the named recipients above and may contain confidential or privileged information. If you have received this message in error, or are not the named recipient(s), please immediately notify the sender by replying to the message and deleting all copies of it from your computer.

To unsubscribe, please reply by returning this message.